Adherence to the Antiemesis National Comprehensive Cancer Network (NCCN) Guideline

• Conditions: Gynecologic Cancer; Chemotherapy-induced Nausea and Vomiting

• Registration Number: NCT03740672
• Lead Sponsor: Lei Li

Brief Summary

This study aims to investigate the adherence to the antiemesis NCCN guideline in Chinese patients of gynecologic malignancies, who are given chemotherapy treatment. The risk of chemotherapy induced nausea and vomiting (CINV) is calculated by the questionnaire supported by the website "CINV Risk Assessment" (http://www.riskcinv.org/).

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-11
• Study First Submitted: 2018-11-10
• Study First Submitted QC: 2018-11-10
• Study First Posted: 2018-11-14
• Last Update Submitted: 2018-11-21
• Study Start: 2018-11-22
• Last Update Posted: 2018-11-26
• Primary Completion: 2019-12-01
• Study Completion: 2019-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 1000

Inclusion Criteria

• Good performance status
• Aged 18 years or older
• Signed an approved informed consents

Exclusion Criteria

• Not meeting all of the inclusion criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
risk of chemotherapy induced nausea and vomiting	One year	The risk of chemotherapy induced nausea and vomiting is calculated by the questionnaire supported by the website "CINV Risk Assessment" (http://www.riskcinv.org/). The difference of patients adhered to and not to NCCN guideline is compared.

Trial Locations

Locations (1)

Lei Li; 🇨🇳 Beijing, Beijing, China